is reportedly in talks to buy a large stake in generic-drug maker
According to a report published Wednesday on the
' Web site, Glaxo may soon buy 10% of South Africa-based Aspen to bolster the U.K. drugmaker's sales in foreign and emerging markets.
The reported negotiations closely follow
that Glaxo might be eying Botox maker
as an acquisition.
Glaxo shares were recently up 1.3% to $29.70.